Analysts See $0.70 EPS for Garmin Ltd. (GRMN); Compugen LTD. – Ordinary Shares (CGEN) Shorts Up By 2.05%

Garmin Ltd. (NASDAQ:GRMN) Logo

Compugen LTD. – Ordinary Shares (NASDAQ:CGEN) had an increase of 2.05% in short interest. CGEN’s SI was 3.27 million shares in April as released by FINRA. Its up 2.05% from 3.21 million shares previously. With 129,400 avg volume, 25 days are for Compugen LTD. – Ordinary Shares (NASDAQ:CGEN)’s short sellers to cover CGEN’s short positions. The stock decreased 9.38% or $0.345 during the last trading session, reaching $3.335. About 183,048 shares traded. Compugen Ltd. (NASDAQ:CGEN) has declined 6.32% since April 17, 2018 and is downtrending. It has underperformed by 10.69% the S&P500. Some Historical CGEN News: 02/04/2018 – COMPUGEN ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH MEDIMMUNE FOR THE DEVELOPMENT OF Bl-SPECIFIC AND MULTI-SPECIFIC ANTIBODY PRODUCTS; 02/04/2018 – Compugen, AstraZeneca unit in cancer drug development deal; 17/04/2018 – COMPUGEN: BAYER PRECLINICAL DATA ON BAY 1905254 SHOWS EFFICACY; 07/03/2018 – Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of Antibody-Based Therapeutics; 02/04/2018 – Compugen Announces Exclusive License Agreement With MedImmune for the Development of Bi-Specific and Multi-Specific Antibody Products; 05/04/2018 – Compugen’s (CGEN) CEO Anat Cohen-Dayag on MedImmune License Agreement Call (Transcript); 02/04/2018 – COMPUGEN LICENSES ANTIBODY PRODUCTS TO ASTRAZENECA’S MEDIMMUNE; 20/03/2018 – Compugen Forms Golden Cross: Technicals; 26/03/2018 – Compugen Announces Appointment of Henry Adewoye, MD, as Chief Medical Officer; 17/04/2018 – COMPUGEN LTD – BAYER PLANS TO ADVANCE CANCER IMMUNOTHERAPY PROGRAM INTO FIRST-IN-HUMAN TRIALS IN 2018

Analysts expect Garmin Ltd. (NASDAQ:GRMN) to report $0.70 EPS on May, 1.They anticipate $0.02 EPS change or 2.94% from last quarter’s $0.68 EPS. GRMN’s profit would be $132.63 million giving it 30.75 P/E if the $0.70 EPS is correct. After having $1.02 EPS previously, Garmin Ltd.’s analysts see -31.37% EPS growth. The stock decreased 1.91% or $1.68 during the last trading session, reaching $86.09. About 502,666 shares traded. Garmin Ltd. (NASDAQ:GRMN) has risen 43.97% since April 17, 2018 and is uptrending. It has outperformed by 39.60% the S&P500. Some Historical GRMN News: 15/05/2018 – Squarepoint Ops Adds Garmin, Exits IBM, Buys More Lululemon: 13F; 13/03/2018 – NORDEA ROLLS OUT PAYMENT SOLUTION FOR FITBIT, GARMIN SMARTWATCH; 02/05/2018 – Garmin Closes Above 50-Day Moving Average: Technicals; 18/04/2018 – Garmin® hosts second Connect IQ™ Developer Summit, announces Connect IQ 3.0 with new apps from Trailforks, Yelp, iHeartRadio; 03/05/2018 – Introducing inReach® Mini from Garmin®, a small but mighty two-way satellite communicator for any adventure; 23/05/2018 – Garmin® introduces the G3000H integrated flight deck to the Part 27 VFR/IFR turbine helicopter market; 13/03/2018 – Nordea: Nordea rolls out payment solution for Fitbit, Garmin smartwatches; 18/04/2018 – Garmin® introduces the Edge® 130 — a compact GPS bike computer designed for use on any ride; 18/04/2018 – Garmin® introduces the Edge® 130 – a compact GPS bike computer designed for use on any ride; 11/04/2018 – The zūmo® 396 motorcycle navigator from Garmin® brings live features to stay connected on every ride

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company has market cap of $199.77 million. The companyÂ’s pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations. It currently has negative earnings. The Company’s antibody drug conjugate target candidates comprise CGEN-15001T, CGEN-15022, CGEN-15029, and CGEN-15137 for oncology; and therapeutic proteins include CGEN-15001, a fusion protein for autoimmune diseases, as well as CGEN myeloid target.

More notable recent Compugen Ltd. (NASDAQ:CGEN) news were published by: Globenewswire.com which released: “Report: Exploring Fundamental Drivers Behind Masco, Ascena Retail Group, Minerva Neurosciences, Compugen, Mountain Province Diamonds, and Luna Innovations — New Horizons, Emerging Trends, and Upcoming Developments – GlobeNewswire” on April 12, 2019, also Benzinga.com with their article: “44 Biggest Movers From Yesterday – Benzinga” published on April 16, 2019, Prnewswire.com published: “Compugen Announces Purchase of Company Shares by its Board of Directors and Members of Management – PRNewswire” on March 26, 2019. More interesting news about Compugen Ltd. (NASDAQ:CGEN) were released by: Prnewswire.com and their article: “Compugen Presents Update on COM701 Phase 1 Trial at the 2019 AACR Annual Meeting – PRNewswire” published on April 03, 2019 as well as Seekingalpha.com‘s news article titled: “Compugen: Anticipating Long-Awaited Pharma Collaboration – Seeking Alpha” with publication date: August 15, 2018.

Among 3 analysts covering Garmin (NASDAQ:GRMN), 0 have Buy rating, 1 Sell and 2 Hold. Therefore 0 are positive. Garmin had 8 analyst reports since January 7, 2019 according to SRatingsIntel. On Tuesday, February 19 the stock rating was maintained by Longbow with “Buy”. The stock has “Equal-Weight” rating by Morgan Stanley on Monday, January 7. As per Wednesday, February 20, the company rating was maintained by Robert W. Baird. As per Thursday, February 21, the company rating was maintained by Morgan Stanley. The firm earned “Sell” rating on Monday, February 25 by Credit Suisse.

Since October 18, 2018, it had 0 buys, and 4 selling transactions for $97.57 million activity. KAO MIN H sold $12.48M worth of stock or 200,000 shares.

Investors sentiment decreased to 1.29 in Q4 2018. Its down 0.11, from 1.4 in 2018Q3. It dived, as 30 investors sold Garmin Ltd. shares while 110 reduced holdings. 58 funds opened positions while 122 raised stakes. 80.59 million shares or 3.30% more from 78.02 million shares in 2018Q3 were reported. Janney Montgomery Scott Llc has 21,525 shares for 0.01% of their portfolio. Tower Cap Limited Co (Trc) has 0.01% invested in Garmin Ltd. (NASDAQ:GRMN). Murphy Pohlad Asset Mngmt Ltd holds 0% in Garmin Ltd. (NASDAQ:GRMN) or 25 shares. Mackenzie Financial Corporation has invested 0.02% of its portfolio in Garmin Ltd. (NASDAQ:GRMN). Johnson Investment Counsel reported 0.01% in Garmin Ltd. (NASDAQ:GRMN). Green Square Capital Limited Liability has invested 0.07% in Garmin Ltd. (NASDAQ:GRMN). Zacks Inv Mgmt owns 0.03% invested in Garmin Ltd. (NASDAQ:GRMN) for 20,388 shares. Commonwealth Of Pennsylvania School Empls Retrmt has invested 0.01% in Garmin Ltd. (NASDAQ:GRMN). Mariner Ltd Liability Company, Kansas-based fund reported 11,524 shares. New York-based Retail Bank Of Ny Mellon has invested 0.03% in Garmin Ltd. (NASDAQ:GRMN). Da Davidson And holds 0.01% of its portfolio in Garmin Ltd. (NASDAQ:GRMN) for 4,610 shares. Signaturefd Ltd Com has invested 0.01% in Garmin Ltd. (NASDAQ:GRMN). Fil Limited has 0% invested in Garmin Ltd. (NASDAQ:GRMN) for 24 shares. Mason Street Advisors Limited Liability Company invested 0.03% of its portfolio in Garmin Ltd. (NASDAQ:GRMN). Ameritas Invest Prtn, Nebraska-based fund reported 2,306 shares.

Garmin Ltd. (NASDAQ:GRMN) Ratings Chart